A Randomized Placebo-controlled Single Center Pilot Study of the Safety and Efficacy of Tralokinumab in Subjects With Moderate to Severe Alopecia Areata
Latest Information Update: 06 Nov 2021
At a glance
- Drugs Tralokinumab (Primary)
- Indications Alopecia areata
- Focus Pharmacodynamics
- 20 Aug 2018 Status changed from recruiting to completed.
- 11 Apr 2017 Planned End Date changed from 1 Oct 2017 to 1 Apr 2018.
- 11 Apr 2017 Planned primary completion date changed from 1 Oct 2017 to 1 Apr 2018.